Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 89,500 KRW
Change Today +2,800 / 3.23%
Volume 201.2K
As of 2:26 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

daewoong pharmaceutical co (069620) Snapshot

Open
86,700
Previous Close
86,700
Day High
90,600
Day Low
84,000
52 Week High
06/26/15 - 151,500
52 Week Low
02/10/15 - 55,400
Market Cap
1.0T
Average Volume 10 Days
154.0K
EPS TTM
3,056
Shares Outstanding
11.6M
EX-Date
12/29/14
P/E TM
29.3x
Dividend
700.00
Dividend Yield
0.78%
Current Stock Chart for DAEWOONG PHARMACEUTICAL CO (069620)

Related News

No related news articles were found.

daewoong pharmaceutical co (069620) Related Businessweek News

No Related Businessweek News Found

daewoong pharmaceutical co (069620) Details

Daewoong Pharmaceutical Co., Ltd. manufactures and sells prescription drugs in South Korea and internationally. The company offers various drugs, including anti-anemic agents, anti-diabetic agents, anti-histamine agents, anti-microbials, anti-neoplastics, anti-obesity agents, anti-osteoporotic agents, biosimilar products, bone and joint diseases, bone grafting materials, cardiovascular drugs, central nervous system drugs, circulatory system agents, and dermatologic products and agents. It also provides gastrointestinal products and agents, health and nutrient supplements, healthcare products, hepatobiliary activators, infection and respiratory products, medical devices and quasi drugs, drugs for metabolic diseases, neuropsychotis drugs, nutraceuticals, oncology drugs, respiratory system agents, skeletal muscle relaxants, urological agents, and wound healing products, as well as anti-pyretic, analgesic, anti-inflammatory agents. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Founded in 1945

daewoong pharmaceutical co (069620) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daewoong pharmaceutical co (069620) Key Developments

3-D Matrix Asia Pte. Ltd and Daewoong Pharmaceutical Co., Ltd. Enter into Partnership Agreement

3-D Matrix Asia Pte. Ltd. and Daewoong Pharmaceutical Co., Ltd. have entered into a partnership agreement for sales and marketing of absorbable local hemostat 'PuraStat®' in ASEAN on July 10, 2015. Based on this agreement, 3DMA will grant an exclusive sales and marketing license to DW in Thailand, Philippines and Vietnam, and a semi-exclusive sales and marketing license in Indonesia where 3DMA already has a local partner with PT. Teguhsindo Lestaritama. 3DMA will receive milestone payments for granting these licenses. This agreement will allow expansion of commercial sales in ASEAN through DW's local networks. As for the exclusive sales and marketing license in Indonesia previously granted to TL, 3DMA has obtained agreement from TL to grant semi-exclusive sales and marketing license to DW, and the two companies will be working together to cater to expanding Indonesian market. DW will be applying for product registration in Thailand, Philippines and Vietnam. Once registered, DW will then market the product within respective markets leveraging on their group's local network. DW expects that 'PuraStat®' will be registered by end of 2015, and that commercial sales will take place by next fiscal year in Thailand, Philippines and Vietnam.

Daewoong Pharmaceutical Enters into Deal with Autotelic to Market Blood Pressure Treatment Olostar in US

Daewoong Pharmaceutical has signed an agreement with Autotelic to export Olostar (olmesatan + rosuvastatin) to the United States. Olostar is a new ARB+statin complex, a combination treatment that was developed by Daewoong and targets high blood pressure and hyperlipidaemia. Under the agreement, biotechnology company Autotelic has received supply and circulation rights for Olostar in the US and Canada and will conduct clinical trials of the treatment in the US before marketing the drug in 2019.

Daewoong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2015

Daewoong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2015., at 09:00 Korea Standard Time. Location: 114 road to bare hall. Agenda: To approve the audit reports and sales reports, the group financial statements and the consolidated financial statements reporting; to appoint external auditor; to appoint directors; and to approve director remuneration.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
069620:KS 89,500.00 KRW +2,800

069620 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
View Industry Companies
 

Industry Analysis

069620

Industry Average

Valuation 069620 Industry Range
Price/Earnings 28.6x
Price/Sales 1.2x
Price/Book 2.0x
Price/Cash Flow 27.5x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEWOONG PHARMACEUTICAL CO, please visit www.daewoong.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.